0.17  0 (0%)		05-22 13:23
Open: 0.164 High: 0.17 Volume: 1,945		Pre. Close: 0.17 Low: 0.164 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.23	1-year :	0.27
Resists	First :	0.2	Second :	0.23
Pivot price	0.17
Supports	First :	0.15	Second :	0.11
MAs	MA(5) :	0.17	MA(20) :	0.16
	MA(100) :	0.39	MA(250) :	0.95
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	48.3	D(3) :	62.1
RSI	RSI(14): 49.7
52-week	High :	4.55	Low :	0.11

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BPTH ] has closed above bottom band by 49.2%. Bollinger Bands are 84.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 52 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.17 - 0.17	0.17 - 0.17
Low:	0.17 - 0.17	0.17 - 0.17
Close:	0.17 - 0.17	0.17 - 0.17

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Thu, 15 May 2025
Bio-Path: Q1 Earnings Snapshot - MySA

Thu, 15 May 2025
Bio-Path: Q1 Earnings Snapshot - Weatherford Democrat

Thu, 01 May 2025
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - Stock Titan

Tue, 18 Feb 2025
US Stocks Mixed; NY State Business Activity Rises In February - Benzinga

Tue, 18 Feb 2025
BPTH stock touches 52-week low at $0.34 amid sharp annual decline - Investing.com

Tue, 18 Feb 2025
Bio-Path Holdings to be delisted from Nasdaq - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	8 (M)
Held by Insiders	7.3e+006 (%)
Held by Institutions	0 (%)
Shares Short	250 (K)
Shares Short P.Month	0 (K)

EPS	-1.194e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-211.1 %
Return on Equity (ttm)	-3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	16285.5
EBITDA (p.s.)	0
Qtrly Earnings Growth	-4.2 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-11 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-0.8

Dividend	0
Forward Dividend	79350
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.